ArticleFish Oil in the Management Of Pediatric Parenteral Nutrition-Associated Liver DiseaseLomangino, KevinAuthor Information Mr. Lomangino is Editor, Clinical Nutrition Insight; E-mail: firstname.lastname@example.org. Mr. Lomangino has disclosed that he has no relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Mr. Lomangino has further disclosed that the parenteral fish oil lipid emulsions Omegaven and SMOFlipid have not been approved by the U.S. Food and Drug Administration for the treatment of parenteral nutrition-associated liver disease. Lippincott Williams & Wilkins is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Dr. Gura disclosed that Children's Hospital Boston has filed a patent application on behalf of Mark Puder and her for the use of Omegaven in PNALD. A licensing agreement is in place between Children's Hospital Boston and Fresenius Kabi. Drs. Matarese and Rollins reported no commercial conflicts. Clinical Nutrition Insight: March 2011 - Volume 37 - Issue 3 - p 1-5 doi: 10.1097/01.NMD.0000395373.04740.d6 Buy Take the CE Test Metrics © 2011 Lippincott Williams & Wilkins, Inc.